MF59®-adjuvanted influenza vaccine (FLUAD®) in children: Safety and immunogenicity following a second year seasonal vaccination

Vaccine

Volumn 27, Issue 45, 2009, Pages 6291-6295

  Vesikari, T ^a   Groth, N ^b   Karvonen, A ^a   Borkowski, A ^c   Pellegrini, M ^b  

^a UNIVERSITY OF TAMPERE MEDICAL SCHOOL   (Finland)

^b NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^c Pharmaserv GmbH and Co KG   (Germany)

Author keywords

Children; FLUAD ; Influenza; MF59

Indexed keywords

INFLUENZA VACCINE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; IMMUNOLOGICAL ADJUVANT; MF59 OIL EMULSION; POLYSORBATE; SQUALENE; VIRUS ANTIBODY;

ANTIBODY TITER; ARTICLE; CHILD; CHILD CARE; CLINICAL TRIAL; COUGHING; DRUG DOSE REGIMEN; DRUG DOSE SEQUENCE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; FINLAND; FOLLOW UP; HUMAN; HUMAN EXPERIMENT; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA; INFLUENZA VACCINATION; INJECTION SITE PRURITUS; IRRITABILITY; MALE; NORMAL HUMAN; PRIORITY JOURNAL; REPEATED DRUG DOSE; RESPIRATORY TRACT INFECTION; RHINITIS; RHINOPHARYNGITIS; SIDE EFFECT; SKIN INDURATION; BLOOD; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOLOGY; INFANT; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS B; PRESCHOOL CHILD; PREVENTIVE HEALTH SERVICE;

ADJUVANTS, IMMUNOLOGIC; ANTIBODIES, VIRAL; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNITY, HUMORAL; IMMUNIZATION PROGRAMS; IMMUNIZATION, SECONDARY; INFANT; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; POLYSORBATES; SQUALENE;

EID: 70349974867     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.02.004     Document Type: Article

References (17)

1. Ghendon Y.Z., Kaira A.N., and Elshina G.A. The effect of mass influenza immunization in children on the morbidity of the unvaccinated elderly. Epidemiol Infect 134 1 (2006) 71-78
2. Principi N., Esposito S., Marchisio P., Gasparini R., and Crovari P. Socioeconomic impact of influenza on healthy children and their families. Pediatr Infect Dis J 22 Suppl. 10 (2003) S207-S210
3. Fiore A.E., Shay D.K., Haber P., Iskander J.K., Uyeki T.M., Mootrey G., et al. Prevention and control of influenza. recommendations of the advisory committee on immunization practices (ACIP), 2007. MMWR Recomm Rep 56 RR-6 (2007) 1-54
4. Mereckiene J., Cotter S., Nicoll A., Levy-Bruhl D., Ferro A., Tridente G., et al. VENICE Project Gatekeepers Group. National seasonal influenza vaccination survey in Europe, 2008. Euro Surveill 13 (Oct 23 2008) 43
5. Jefferson T., Rivetti A., Harnden A., Di Pietrantonj C., and Demicheli V. Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev 2 2 (2008) [CD004879]
6. Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59C. 1-adjuvanted vaccine. Vaccine 19 (2001) 2673-2680
7. ® adjuvant. Pediatr Infect Dis J; in press.
8. Menegon T., Baldo V., Bonello C., Dalla Costa D., Di Tommaso A., and Trivello R. Influenza vaccines: Antibody responses to split virus and MF59-adjuvanted subunit virus in an adult population. Eur J Epidemiol 15 6 (1999) 573-576
9. Iwane M.K., Edwards K.M., Szilagyi P.G., Walker F.J., Griffin M.R., Weinberg G.A., et al. Population-based surveillance for hospitalizations associated with respiratory syncytial virus, influenza virus, and parainfluenza viruses among young children. Pediatrics 113 6 (2004) 1758-1764
10. Poehling K.A., Edwards K.M., Weinberg G.A., Szilagyi P., Staat M.A., Iwane M.K., et al. The under-recognized burden of influenza illness in young children. N Engl J Med 355 1 (2006) 31-40
11. Smith N.M., Bresee J.S., Shay D.K., Uyeki T.M., Cox N.J., and Strikas R.A. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 55 RR-10 (2006) 1-42
12. Fiore A.E., Shay D.K., Broder K., Iskander J.K., Uyeki T.M., Mootrey G., et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP) 2008. MMWR 57 (2008) 1-60 [Early Release]
13. O'Hagan D.T. MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection. Expert Rev Vaccines 6 5 (2007) 699-710
14. Banzhoff A., Nacci P., and Podda A. A new MF59-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: results from an immunogenicity meta-analysis. Gerontology 49 3 (2003) 177-184
15. Iorio A.M., Francisci D., Camilloni B., Stagni G., De Martino M., Toneatto D., et al. Antibody responses and HIV-1 viral load in HIV-1-seropositive subjects immunised with either the MF59-adjuvanted influenza vaccine or a conventional non-adjuvanted subunit vaccine during highly active antiretroviral therapy. Vaccine 21 25-26 (2003) 3629-3637
16. Baldo V., Baldovin T., Floreani A., Carraro A.M., and Trivello R. Family Medicine Group of Pianiga. MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18-60 years of age) with chronic diseases who are at risk of post-influenza complications. Vaccine 25 20 (2007) 3955-3961
17. Paschke R., Pollok M., Geiger H., Ketteler M., Abendroth D., Gunther M., et al. Increased immunogenicity with an MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in renal transplant recipients. J Prev Med Hyg 44 (2003) 79-84